EMG
ABMD

Ellington Management Group’s Abiomed Inc ABMD Stock Holding History

Ellington Management Group’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,300
Closed -$556K – 870
2017
Q3 		$556K Buy
3,300
+800
+32% +$121K 0.1% 184
2017
Q2 		$358K Sell
2,500
-1,800
-42% -$242K 0.05% 346
2017
Q1 		$538K Buy
+4,300
New +$498K 0.02% 289
2016
Q2 		– Sell
-3,300
Closed -$313K – 534
2016
Q1 		$313K Buy
3,300
+700
+27% +$59.1K 0.13% 226
2015
Q4 		$235K Buy
+2,600
New +$221K 0.08% 380

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ellington Management Group's ABMD Position: Q4 2017 in Review

Ellington Management Group sold out of Abiomed Inc (ABMD) in Q4 2017, closing a stake of 3,300 shares — an estimated $556K sold.

Ellington Management Group first reported a position in ABMD in Q4 2015 and held it in 5 quarters. The position peaked at $556K in Q3 2017. 361 funds tracked by Wall St. Rank hold ABMD as of Q4 2017.

  • Ellington Management Group reported no remaining Abiomed Inc position as of Q4 2017 after selling out during the quarter.
  • Ellington Management Group sold 3,300 Abiomed Inc shares in Q4 2017, an estimated $556K.
  • Ellington Management Group first reported a position in Abiomed Inc in Q4 2015 and held it in 5 quarters.
  • Ellington Management Group's Abiomed Inc position peaked at $556K in Q3 2017.
  • 361 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2017.

Based on Ellington Management Group's 13F filing for Q4 2017, filed 14 Feb 2018.